Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer - Abstract

BACKGROUND: Previous publications have demonstrated conflicting results regarding body mass index (BMI) and prostate cancer (CaP) outcomes after definitive radiotherapy (RT) before the dose escalation era.

The goal of the current study was to determine whether increasing BMI was associated with outcomes in men with localized CaP who were treated with dose-escalated RT.

METHODS: The authors identified patients with localized (T1b-T4N0M0) CaP who were treated with definitive intensity-modulated RT and image-guided RT from 2001 through 2010. BMI was analyzed as a continuous variable. Adjusting for confounders, multivariable competing risk and Cox proportional hazards regression models were used to assess the association between BMI and the risk of biochemical failure (BF), distant metastases (DM), cause-specific mortality (CSM), and overall mortality.

RESULTS: Of the 1442 patients identified, approximately 20% had a BMI < 25 kg/m2, 48% had a BMI of 25 to 29.9 kg/m2 , 23% had a BMI of 30 to 34.9 kg/m2 , 6% had a BMI of 35 to 39.9 kg/m2 , and 4% had a BMI of ≥40 kg/m2 . The median follow-up was 47.6 months (range, 1-145 months), with a median age of 68 years (range, 36-89 years). The median dose was 78 grays (range, 76-80 grays) and 30% of patients received androgen deprivation therapy. Increasing BMI was found to be inversely associated with age (P< .001) and pretreatment prostate-specific antigen level (P = .018). On multivariable analysis, increasing BMI was associated with an increased risk of BF (hazard ratio [HR], 1.03; 95% confidence interval [95% CI], 1.00-1.07 [P = .042]), DM (HR, 1.07; 95% CI, 1.02-1.11 [P = .004]), CSM (HR, 1.15; 95% CI, 1.07-1.23 [P< .001]), and overall mortality (HR, 1.05; 95% CI, 1.02-1.08 [P = .004]).

CONCLUSIONS: For patients with CaP receiving dose-escalated intensity-modulated RT with daily image-guidance, increasing BMI appears to be associated with an increased risk of BF, DM, CSM, and overall mortality.

Written by:
Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, Kutikov A, Viterbo R, Horwitz EM.   Are you the author?
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Urology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.


Reference: Cancer. 2015 May 29. Epub ahead of print.
doi: 10.1002/cncr.29472

PubMed Abstract
PMID: 26033633 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.